BACKGROUND: Metabolic complications, including type 2 diabetes mellitus and metabolic syndrome, are increasingly recognized among HIV-infected individuals. Low vitamin D levels increase the risk of type 2 diabetes mellitus, and vitamin D supplementation has been shown to decrease the risk of type 2 diabetes mellitus in patients without HIV infection. OBJECTIVES: The primary objective was to determine whether vitamin D deficiency (serum 25-hyrdoxyvitamin D <20 ng/ml) was associated with type 2 diabetes mellitus among HIV-infected patients. Our secondary objective was to determine whether vitamin D deficiency was associated with metabolic syndrome in HIV. METHODS: We conducted a cross-sectional study among participants enrolled in the prospective Modena (Italy) HIV Metabolic Clinic Cohort. Clinical and laboratory data, including history of type 2 diabetes mellitus, fasting blood glucose, components of metabolic syndrome, and 25-hydroxyvitamin D levels, were obtained for all participants. RESULTS: After adjusting for vitamin D supplementation, sex, age, body mass index, and hepatitis C virus co-infection, vitamin D deficiency was associated with type 2 diabetes mellitus [adjusted odds ratio (OR) 1.85; 95% confidence interval (CI) 1.03-3.32; P = 0.038]. The association between vitamin D deficiency and metabolic syndrome was not significant after adjusting for vitamin D supplementation, sex, age and body mass index (adjusted OR 1.32; 95% CI 1.00-1.75; P = 0.053). CONCLUSIONS: Our study demonstrates an association between vitamin D deficiency and type 2 diabetes mellitus. Clinical trials are needed to better characterize the association between vitamin D deficiency and type 2 diabetes mellitus in HIV infection and to evaluate whether vitamin D is able to prevent or delay the onset of type 2 diabetes mellitus.
BACKGROUND: Metabolic complications, including type 2 diabetes mellitus and metabolic syndrome, are increasingly recognized among HIV-infected individuals. Low vitamin D levels increase the risk of type 2 diabetes mellitus, and vitamin D supplementation has been shown to decrease the risk of type 2 diabetes mellitus in patients without HIV infection. OBJECTIVES: The primary objective was to determine whether vitamin D deficiency (serum 25-hyrdoxyvitamin D <20 ng/ml) was associated with type 2 diabetes mellitus among HIV-infectedpatients. Our secondary objective was to determine whether vitamin D deficiency was associated with metabolic syndrome in HIV. METHODS: We conducted a cross-sectional study among participants enrolled in the prospective Modena (Italy) HIV Metabolic Clinic Cohort. Clinical and laboratory data, including history of type 2 diabetes mellitus, fasting blood glucose, components of metabolic syndrome, and 25-hydroxyvitamin D levels, were obtained for all participants. RESULTS: After adjusting for vitamin D supplementation, sex, age, body mass index, and hepatitis C virus co-infection, vitamin D deficiency was associated with type 2 diabetes mellitus [adjusted odds ratio (OR) 1.85; 95% confidence interval (CI) 1.03-3.32; P = 0.038]. The association between vitamin D deficiency and metabolic syndrome was not significant after adjusting for vitamin D supplementation, sex, age and body mass index (adjusted OR 1.32; 95% CI 1.00-1.75; P = 0.053). CONCLUSIONS: Our study demonstrates an association between vitamin Ddeficiency and type 2 diabetes mellitus. Clinical trials are needed to better characterize the association between vitamin Ddeficiency and type 2 diabetes mellitus in HIV infection and to evaluate whether vitamin D is able to prevent or delay the onset of type 2 diabetes mellitus.
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Anastassios G Pittas; Bess Dawson-Hughes; Tricia Li; Rob M Van Dam; Walter C Willett; Joann E Manson; Frank B Hu Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Mario Cozzolino; Marcos Vidal; Maria Vittoria Arcidiacono; Pablo Tebas; Kevin E Yarasheski; Adriana S Dusso Journal: AIDS Date: 2003-03-07 Impact factor: 4.177
Authors: Todd T Brown; Xiuhong Li; Stephen R Cole; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Joan S Chmiel; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Chris T Longenecker; Corrilynn O Hileman; Teresa L Carman; Allison C Ross; Shabnam Seydafkan; Todd T Brown; Danielle E Labbato; Norma Storer; Vin Tangpricha; Grace A McComsey Journal: Antivir Ther Date: 2011-11-17
Authors: Jennifer Jao; Laura Freimanis; Marisa M Mussi-Pinhata; Rachel A Cohen; Jacqueline P Monteiro; Maria L Cruz; Rhoda S Sperling; Andrea Branch; George K Siberry Journal: Int J Gynaecol Obstet Date: 2015-04-11 Impact factor: 3.561
Authors: Oluwatoyin M Adeyemi; Britt Livak; Jennifer Orsi; Marshall J Glesby; Maria C Villacres; Kathleen M Weber; Anjali Sharma; Elizabeth Golub; Mary Young; Mardge Cohen; Phyllis C Tien Journal: AIDS Patient Care STDS Date: 2013-05-15 Impact factor: 5.078
Authors: Risa M Hoffman; Jordan E Lake; Holly M Wilhalme; Chi-Hong Tseng; Judith S Currier Journal: AIDS Res Hum Retroviruses Date: 2015-11-16 Impact factor: 2.205